Astellas Advances Alefacept To Phase II For Renal Transplant Rejection Prevention
This article was originally published in PharmAsia News
Executive Summary
Taking a step to expand its immunosuppressant pipeline, Astellas is initiating Phase II clinical trials in North America and Europe for its biologic ASP0485 (alefacept) to prevent renal transplant rejection, the firm announced Sept. 12